V. Sekar

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

Mark Nelson, Pierre‐Marie Girard, Ryan DeMasi et al. · Journal of Antimicrobial Chemotherapy · 2010 · 56 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Effects of ritonavir‐boosted darunavir <i>vs</i>. ritonavir‐boosted atazanavir on lipid and glucose parameters in HIV‐negative, healthy volunteers

F Tomaka, Éric Lefebvre, V. Sekar et al. · HIV Medicine · 2009 · 44 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL

Stefan Zeuzem, Thomas Berg, Edward Gane et al. · Journal of Hepatology · 2012 · 34 citations

Life Sciences, Infectious Diseases, Molecular Virology +15

1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT

Stefan Zeuzem, Graham R. Foster, Michael Fried et al. · Journal of Hepatology · 2011 · 29 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Effect of Repeated Doses of Darunavir plus Low-Dose Ritonavir on the Pharmacokinetics of Sildenafil in Healthy Male Subjects

V. Sekar, Éric Lefebvre, Tine De Marez et al. · Clinical Drug Investigation · 2008 · 25 citations

Medicine, Pharmacokinetics, Pharmacology +5